TD Asset Management
HRTX icon

TD Asset Management’s Heron Therapeutics HRTX Stock Holding History

TD Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-394,600
Closed -$817K – 1261
2025
Q2 		$817K Hold
394,600
– – ﹤0.01% 1086
2025
Q1 		$868K Buy
+394,600
New +$766K ﹤0.01% 1091

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TD Asset Management's HRTX Position: Q3 2025 in Review

TD Asset Management sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 394,600 shares — an estimated $817K sold.

TD Asset Management first reported a position in HRTX in Q1 2025 and held it in 2 quarters. The position peaked at $868K in Q1 2025. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • TD Asset Management reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TD Asset Management sold 394,600 Heron Therapeutics shares in Q3 2025, an estimated $817K.
  • TD Asset Management first reported a position in Heron Therapeutics in Q1 2025 and held it in 2 quarters.
  • TD Asset Management's Heron Therapeutics position peaked at $868K in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on TD Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.